16:54:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-02-26 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-21 Ordinarie utdelning NYKD 0.00 NOK
2024-05-16 Årsstämma 2024
2024-05-14 Kvartalsrapport 2024-Q1
2024-02-28 Bokslutskommuniké 2023
2023-11-15 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-16 Kvartalsrapport 2023-Q1
2023-05-12 Ordinarie utdelning NYKD 0.00 NOK
2023-05-11 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-16 Kvartalsrapport 2022-Q1
2022-05-13 Ordinarie utdelning NYKD 0.00 NOK
2022-05-12 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning NYKD 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split NYKD 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma


ListaOB Match
Nykode Therapeutics är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.
2020-10-07 08:30:00
Company is admitted to trading on the electronic trading platform Merkur Market
as of October 7, 2020 under the ticker “VACC-ME”.

Oslo, Norway, October 7, 2020 – Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of novel immunotherapies,
announces that its shares have been admitted to trading on the Norwegian trading
platform Merkur Market (“Merkur”), owned and operated by Oslo Børs, from today
October 7, 2020.

Vaccibody will trade under the ticker “VACC-ME”. The Company currently has
283,627,680 outstanding shares of NOK 0.01 each, all of which are registered in
the Norwegian Central Securities Depository (VPS) under ISIN NO 0010714785.

The Chair of the Board of Directors, Anders Tuv, comments: “Due to the news
flow, Vaccibody has over the past twelve months generated significant interest
from both Norwegian and international investors. The list of shareholders has
almost tripled during the past year and now counts more than 800 individual
shareholders. The registration and fully electronic trading on Merkur is a
logical next step for Vaccibody and will further facilitate the transparency of
trading in and the liquidity of the Company’s shares.”

About Vaccibody
Vaccibody is a clinical-stage biopharmaceutical company dedicated to the
discovery and development of novel immunotherapies. The Company is using the
Vaccibody technology to generate best-in-class therapeutics against cancers and
infectious diseases with a high unmet medical need.

Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use,
based on a deep understanding of immunological principles. Vaccibody’s vaccines
specifically target Antigen Presenting Cells (APC), which are essential for
inducing rapid, strong and specific immune responses and elicit efficacious
clinical responses. By intelligent design, Vaccibody’s vaccines can be tailored
to induce the desired immune response profile correlating with protection for
each specific disease with any given antigen. Hence, the Vaccibody vaccine
platform has the potential to address many disease areas with a high unmet
medical need such as cancer and infectious diseases. Vaccibody has
collaborations with Roche and Genentech, and Nektar Therapeutics and will pursue
further collaborations and strategic partnerships to maximize the value of its
technology platform.

Vaccibody’s shares are traded on Merkur Market, a trading platform operated and
wholly owned by Oslo Børs ASA, the Oslo Stock Exchange.

Further information about the Company may be found at http://www.vaccibody.com

CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509

Vaccibody AS
Oslo Research Park
Gaustadalléen 21
0349 Oslo, Norway